Press Releases

30 June 2006


Inpharmatica Ltd., the selective drug discovery company, today announces that Eli Lilly and Company has licensed Admensa Interactive, Inpharmatica’s innovative suite of predictive drug absorption, distribution, metabolism and excretion (ADME) models and compound prioritisation tools. Lilly took the decision to license Admensa Interactive after thorough evaluation.

Commenting on the announcement, John Lisle, Chief Executive Officer of Inpharmatica, said “We are delighted that Lilly, with its significant in-house strength in computational ADME, has chosen AI to augment its discovery support. More than ten top pharma and biotech companies have licensed Inpharmatica’s innovative suite of predictive models and decision tools for drug discovery. ”

Admensa Interactive combines state-of-the-art predictive models with a highly intuitive desktop interface combining model output with project data from other sources in an integrated selection and visualisation platform to drive effective decisions on the best compounds for progression against project criteria.

Admensa Interactive is a major component of Inpharmatica’s range of gene-to-candidate technologies which integrate biology and chemistry-based drug discovery activities. Inpharmatica’s platform ranges from target selection based on druggability, through rapid identification of hits to selection of high quality leads and pre-clinical candidates, which are prioritised on the basis of good drug-like characteristics.

For more information on gaining access to Admensa Interactive and its capabilities, please visit click here

About Inpharmatica Founded in 1998, Inpharmatica uses predictive informatics in genomics, medicinal chemistry and ADME to improve the speed and productivity of drug discovery. The company employs around 90 professionals at its UK locations in London and Cambridge, with business development in North America and Japan. Inpharmatica’s unique proprietary technologies and skills are utilised in major discovery laboratories worldwide including Serono, Pfizer, GSK, Novartis, Sanofi-Aventis, P&G Pharmaceuticals, and Daiichi.

Inpharmatica is unique in offering discovery technologies and services which span the full breadth of research from gene through to candidate selection: the core elements are fully integrated, enabling customers to access the full end-to-end technologies, or individual components and services as required.